Latest News

BerGenBio plans IPO and partners with MSD

To activate the Axl kinase and transmit its signal to the cell nucleus, the GAS6 ligand has to bind externally and the energy carrier ATP (green) internally. Inhibitors (orange) prevent transmission of the signal, © MPI for Biochemistry


by tg

Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.

The IPO, underwritten by ABG Sundal Collier, Arctic Securities and DNB Markets, includes a public offering to institutional and retail investors in Norway and Sweden, and a private placement to certain institutional investors internationally.

BerGenBio’s lead candidate BGB324 (formerly R-428), licensed from Rigel Pharmaceuticals in 2010, has passed Phase Ib testing in acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), and non-small cell lung cancer (NSCLC, in combination with erlonitib) patients. On the day of the IPO announcement, BerGenBio additionally said it will start two collaborative Phase II combination studies of BGB324 with Merck & Co’s PD-1 checkpoint inhibitor pembrolizumab this year in patients with adenocarcinoma (NSCLC) and and triple-negative breast cancer (TNBC). The clinical trials will be sponsored by BerGenBio while Merck will provide the trial with Keytruda. The rights to the study results will be shared. Financial details were not disclosed. Preclinical data from 2015 indicate that BGB324 showed enhanced tumour clearance, survival and tumour infiltration of cytotoxic T lymphocytes compared with checkpoint inhibition (CTLA-4, PD1) alone.

Axl kinase promotes cancer cell migration, epithelial-mesenchymal transition (EMT) and tumour cell proliferation as well as therapy resistance. The protein is overexpressed in the membranes of 60% of lung cancers, highly invasive breast cancers, and pancreatic cancer as well as in AML, where it serves as independent prognostic marker. Additionally, several studies suggest that overexpression of AXL may result in resistance to both targeted therapies and conventional chemotherapy in different models, such as lung cancer, breast cancer resistant to EGFR inhibition, esophageal carcinoma, gastrointestinal stromal tumours, and AML. 

Besides its selective Axl kinase inhibitor, the Norwegian company also has an anti-Axl kinase antibody and an antibody drug conjugate (ADC) under preclinical development. Treatment responders are set to be stratified prior to therapy by a companion diagnostics test that measures Axl kinase expression.

Food specialist Standing Ovation SA raises €12m

The company wants to use the assets to accelerate industrial-scale production of its vegan casein and milk protein derivatives. Standing...

Novadip Biosciences SA raises €40m

Belgian regenerative medicine specialist Novadip Biosciences has raised €40m to push clinical development of its two investigational adipose stem...

Audi and Krajete create CO2 air capture plant

The plant, which binds the greenhouse gas CO2 directly from the air to an inorganic carrier material without pre-drying and stores it in a highly...

Bone Therapeutics merges with Medsenic and changes name

The combination of Medsenic and Bone Therapeutics will expand  Bone Therapeutics' allogeneic cell therapy-based product portfolio in orthopedics...

Standing Ovation wins Industria Biotec’s start-up pitch

The French food-tech company Standing Ovation has won the first start-up pitch at Industria Biotec, which takes place today in Berlin. Founded in...

Novo Nordisk Foundation funds Plant2Food with €27m

The focus of Plant2Food is to create a library of fundamental knowledge about the properties of plants and how they could replace food products that...

Novo Nordisk funds API manufacturing with €726m

Novo Nordisk’s latest expansion of R&D as well as production capacity is motivated by the need to generate more of its GLP-1 agonist semaglutide,...